Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Regenocyte is a biotechnology company and medical provider specializing in autologous adult stem cell therapies for chronic and debilitating conditions. The company focuses on treating cardiovascular and pulmonary diseases, including congestive heart failure, cardiomyopathy, and COPD, by utilizing a patient's own bone marrow-derived stem cells. These cells are processed and re-administered to promote tissue repair and stimulate the body's natural healing processes. Regenocyte operates through specialized treatment centers, positioning its services as an alternative for patients who have not found success with traditional surgical or pharmacological interventions. Their approach emphasizes the safety of using autologous cells to minimize the risk of rejection or complications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Regenocyte Therapeutic.